Research

Research alliance within a compliance-conscious framework.

Ethically approved research. Defined institutional scope. Scientific independence.

Rigorous research requires time, structure, and the appropriate institutional oversight. HarmoniXCell supports IRB-supervised research initiatives conducted independently, governed by formal ethics review, and kept structurally separate from commercial activity.

Every research collaboration begins with a clearly defined scope. The science remains independent. The boundaries remain documented.

Research Governance Principles
Collaboration Pathway
Research Initiatives in Development
Data Methodology

  • Collaboration

  • Evidence

  • Governance

  • Translation

IRB OVERSIGHT

Every research initiative conducted within or affiliated with the HarmoniX ecosystem is conducted under Institutional Review Board supervision. HarmoniXCell does not participate in research activities that lack appropriate ethics oversight.

Independence from Commercial Programs

Research activities are structurally separated from commercial programs. Investigational data is not positioned as commercial evidence, market validation, or a basis for efficacy claims.

No Protocol Direction

HarmoniXCell does not design, direct, or influence clinical protocols. Where it supports IRB-supervised studies, it does so in an infrastructure and coordination capacity within defined and documented scope.

Data Methodology

Integrated Data Architecture HarmoniXNumbers Partnership

In collaboration with HarmoniXNumbers, investigational studies within the HarmoniX ecosystem integrate pre- and post-intervention biomarker monitoring alongside validated Patient-Reported Outcome instruments. This methodology is designed to produce more complete scientific datasets than single-instrument approaches.

Investigational Studies

This data architecture is a scientific design feature of the investigational studies. It is not a commercial differentiation claim or a representation of therapeutic effectiveness. Data generated through these studies belongs to the scientific record and will be subject to appropriate peer review.

Research Initiatives in Development

2026 Pipeline – IRB-Supervised Investigational Studies

The following research initiatives are in the pre-approval pipeline for 2026. These are investigational studies conducted under IRB supervision and in accordance with applicable FDA regulations. They are not clinical services and do not constitute evidence of FDA approval for any therapy or product.

Investigational Study A — Musculoskeletal Focus

An IRB-supervised investigational study developed in collaboration with an independent clinical research partner (MD Spine Care). National in scope, with additional institutional collaborators anticipated post-IRB approval. Designed to generate peer-reviewed scientific data under formal ethics oversight.

Note: This is an investigational study. Its subject matter has not been evaluated by the FDA for the indication under study. Results are scientific data, not evidence of therapeutic efficacy or regulatory approval.

Investigational Study B — Cardiovascular Focus

An IRB-supervised investigational study developed in collaboration with institutional cardiology partners in Texas. Supported by Bobby Thomure, former Chairperson of the American Heart Association. Designed to contribute to the published scientific literature under appropriate institutional oversight.

Note: This is an investigational study. Its subject matter has not been evaluated by the FDA for the indication under study. Results are scientific data, not evidence of therapeutic efficacy or regulatory approval.